Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

NCT04908813 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: HLX22
DRUG: Placebo
DRUG: Trastuzumab
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

Shanghai Henlius Biotech